BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/26/2025 4:21:38 AM | Browse: 123 | Download: 482
 |
Received |
|
2024-08-26 02:45 |
|
Peer-Review Started |
|
2024-09-05 01:40 |
|
First Decision by Editorial Office Director |
|
2024-12-29 02:05 |
|
Return for Revision |
|
2024-12-29 02:05 |
|
Revised |
|
2025-01-10 14:33 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-02-10 02:33 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-02-10 04:56 |
|
Articles in Press |
|
2025-02-10 04:56 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-02-12 02:16 |
|
Publish the Manuscript Online |
|
2025-02-26 04:21 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Nab-paclitaxel plus capecitabine as a first-line regimen for advanced biliary tract cancers: Feasible or not feasible?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jian-Qiang Chen and Xiang Lan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xiang Lan, MD, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing 400016, China. lanxiangkeyan@163.com |
| Key Words |
Nab-paclitaxel; Capecitabine; Biliary tract cancers; Systemic therapy; First-line regimen |
| Core Tip |
We investigated the development and efficacy of systemic therapy for advanced biliary tract cancers (BTCs) and concluded that paclitaxel plus capecitabine is a promising first-line regimen for advanced BTCs. |
| Publish Date |
2025-02-26 04:21 |
| Citation |
Chen JQ, Lan X. Nab-paclitaxel plus capecitabine as a first-line regimen for advanced biliary tract cancers: Feasible or not feasible? World J Gastroenterol 2025; 31(10): 100771 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i10/100771.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i10.100771 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
